During the 2025 European Society of Cataract and Refractive Surgeons (ESCRS) conference, Past President of the American Society of Cataract and Refractive Surgery (ASCRS) Dr. Vance Thompson was interviewed by Eyewire. Dr. Thompson shared significant information on Avisi’s VisiPlate® and VisiPlate-S products to treat glaucoma. These innovative devices were created to treat varying levels […]
Avisi Technologies, Inc. announced it has secured $10.7 million in a recent Series A financing round to support the SAPPHIRE pivotal clinical trial evaluating its novel glaucoma treatment device: the VisiPlate. Where to begin with this? For a quick refresh on Avisi, click here. As for the focus of this coverage: We’ll start with the VisiPlate—its flagship minimally-invasive bleb surgery […]
Life Science Intelligence announces a successful week for MedTech companies within the LSI community. As part of the announcement, Avisi Technologies was highlighted, and their $10.7M Series A fundraising round led by MedVenture Partners, bringing the company’s total funding to $21.7M. The funding will support the company’s pivotal clinical trial SAPPHIRE, which received FDA IDE […]
Avisi Technologies announces Series A financing for SAPPHIRE pivotal trial of VisiPlate® novel glaucoma treatment Round led by MedVenture Partners with participation from new investors and existing investors VisiPlate® shunt features unique design with a novel metamaterial, thinner than a human hair Redwood City, CA – February 25, 2026 – /PR Newswire/ Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, announces the closing of $10.7M in new financing. […]
The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sacramento Eye Consultants, in Sacramento, California. SAPPHIRE Trial is a prospective, multicenter, open-label clinical trial with 1-year follow up, evaluating safety and effectiveness of VisiPlate® aqueous shunt in glaucoma patients. VisiPlate® shunt is uniquely designed: novel metamaterial, thinner […]
Almost half of patients medication free at 12 months. Vast majority of patients achieved significant IOP reduction on the same or fewer medications. Strong 12-month safety and efficacy results: no serious adverse events. Redwood City, CA – November 3, 2025 – /eyewire/ Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, presented […]
